Literature DB >> 24903726

A midline for oxaliplatin infusion: the myth of safety devices.

Ben Masters1, Tamas Hickish2, Esther Uña Cidon2.   

Abstract

Oxaliplatin is a platinum compound mainly used in the treatment of colorectal cancer. According to its manufacturer it is not considered vesicant agent though it has been shown to cause severe tissue damage if extravasation occurs in large doses. Several cases of extravasation have been reported; most of them from incorrectly placed peripheral cannula or incorrect use of central venous access devices. To reduce these risks, peripherally inserted central catheters and midline catheters have been increasingly used and are especially helpful if poor peripheral venous access. Midlines are mainly used for patients not receiving vesicant drugs, and are generally inserted without radiological guidance. They are believed to be safe, but we present the first ever-documented oxaliplatin extravasation injury from a midline catheter. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24903726      PMCID: PMC4054494          DOI: 10.1136/bcr-2014-204360

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Extravasation of Oxaliplatin (Eloxatin((R))) - Clinical Course.

Authors:  M. Baur; H.-R. Kienzer; T. Rath; C. Dittrich
Journal:  Onkologie       Date:  2000-10

2.  Extravasations of oxaliplatin.

Authors:  Albrect Kretzschmar; Daniel Pink; Peter Thuss-Patience; Bernd Dörken; Peter Reichert; Robert Eckert
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

Review 3.  Extravasation of systemic hemato-oncological therapies.

Authors:  R A Ener; S B Meglathery; M Styler
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

Review 4.  Venous access: a practical review for 2009.

Authors:  Edward Cheung; Mark O Baerlocher; Murray Asch; Andrew Myers
Journal:  Can Fam Physician       Date:  2009-05       Impact factor: 3.275

5.  A case report of oxaliplatin extravasation.

Authors:  K F Foo; M Michael; G Toner; J Zalcberg
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

Review 6.  Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.

Authors:  Todd A Theman; Tristan L Hartzell; Indranil Sinha; Kathleen Polson; Jeffrey Morgan; George D Demetri; Dennis P Orgill; Suzanne George
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

Review 7.  Management of extravasation of oxaliplatin.

Authors:  Mário L de Lemos; Susan Walisser
Journal:  J Oncol Pharm Pract       Date:  2005-12       Impact factor: 1.809

8.  The use of hyaluronidase in the treatment of intravenous extravasation injuries.

Authors:  W V Raszka; T K Kueser; F R Smith; J W Bass
Journal:  J Perinatol       Date:  1990-06       Impact factor: 2.521

9.  Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results.

Authors:  G Bertelli; D Dini; G B Forno; A Gozza; S Silvestro; M Venturini; R Rosso; P Pronzato
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

  9 in total
  2 in total

1.  Cervical dissecting extravasation of oxaliplatin: A case report.

Authors:  Jorge Hernando; Judit Riera-Arnau; Maria Roca; Alejandro Garcia; Jaume Capdevila
Journal:  Mol Clin Oncol       Date:  2022-01-12

2.  Safety of locating the tip of a medium-long catheter at the axillary front and clavicle midline: A protocol for systematic review and meta-analysis.

Authors:  Yali Zhao; Jie Geng; Xing Wu; Suiting Xiong; Liwei Wang; Juanxia Wang; Haijv Ma; Fengxian Wei; Zhihong Wei
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.